French researchers writing in Arthritis and Rheumatology describe a biomarker that may determine the risk of mortality in patients with dermatomyositis who develop cancer, a common outcome in adults.
Patients with giant cell arteritis treated weekly or bi-weekly with tocilizumab and a prednisone taper experience better outcomes than those treated only with prednisone, a new study shows.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
